RASopathy Biorepository

Investigation Into the Natural History and Metabolic and Molecular Basis of RASopathies.

Sponsors

Lead Sponsor: Children's Hospital Medical Center, Cincinnati

Source Children's Hospital Medical Center, Cincinnati
Brief Summary

The RASopathies are a group of developmental disorders caused by genetic changes in the genes that compose the Ras/mitogen activated protein kinase (MAPK) pathway. New RASopathies are being diagnosed frequently. This pathway is essential in the regulation of the cell cycle and the determination of cell function. Thus, appropriate function of this pathway is critical to normal development. Each syndrome in this group of disorders has unique phenotypic features, but there are many overlapping features including facial features, heart defects, cutaneous abnormalities, cognitive delays, and a predisposition to malignancies. This research study proposes to collect and store human bio-specimens from patients with suspected or diagnosed RASopathies. Once obtained, blood and/or tissue samples will be processed for: metabolic function studies, biomarkers, genetic studies, and/or the establishment of immortalized cell lines. In addition, data from the medical record (including neuropsychological evaluations) and surveys will be stored to create a longitudinal database for research conducted at CCHMC or at other research institutions.

Detailed Description

Patients who are being evaluated for a RASopathy may have overlapping features, but the disorders individually can be exceedingly rare and many are not yet well characterized. Additionally, available clinical testing is not always diagnostic in this group of patients. The investigators propose to study disorders across the RAS/MAPK pathway, identifying both commonalities and differences, under one unified ongoing research protocol. The investigators propose: 1. To investigate the metabolic and molecular basis of established and suspected RASopathies. 2. Collect specimens derived from blood, buccal cells, sputum, urine, bone marrow, tumor tissue and residual specimens, including but not limited to pleural fluid, ascetic fluid, chyle, skin, lung, lymphatic or renal tissue and/or bronchoalveolar lavage fluid, tissue specimens, and/or cells that are left over from clinical procedures from enrolled patients for research purposes only. 3. Non-invasive or minimally invasive procedures to collect tissues for research purposes only, such as saliva, skin, or blood samples are also allowed. The collection of all samples from minor subjects will be done only if it is safe for the participant. Clinical studies will take precedence over research procedures. 4. Collect demographic information, medical history, and clinical test results to create a longitudinal research database of participants with suspected or diagnosed RASopathies. Participants will also complete surveys to be included in the research database (see "Research Database" section for details). 5. Provide a facility for long-term storage of bio-specimens and clinical data from participants with suspected or diagnosed RASopathies and their unaffected relatives.

Overall Status Recruiting
Start Date June 27, 2017
Completion Date December 2065
Primary Completion Date December 2065
Study Type Observational [Patient Registry]
Primary Outcome
Measure Time Frame
Collection of biospecimen 50 years
Collection of medical history 50 years
Secondary Outcome
Measure Time Frame
Release of Specimens and Clinical Data to Other Investigators for use in RASopathy Research 50 years
Enrollment 1000
Condition
Eligibility

Sampling Method: Non-Probability Sample

Criteria:

Inclusion Criteria: - Patients with a suspected or known diagnosis of any of the group of disorders known as RASopathies (e.g., Neurofibromatosis, Costello Syndrome, Noonan Syndrome). Diagnosis may be made clinically and/or confirmed through genetic testing. - Unaffected relatives of patients with a suspected or known diagnosis of any of the group of disorders known as RASopathies. Exclusion Criteria: - Individuals who do not have a suspected or definite diagnosis of a RASopathy. - Individuals who do not have a relative with a suspected or definite diagnosis of a RASopathy. - Patients who do not have the ability/capacity to undergo the informed consent process OR whose parent/legal guardian is unable to undergo the informed consent process.

Gender: All

Minimum Age: N/A

Maximum Age: N/A

Healthy Volunteers: Accepts Healthy Volunteers

Overall Official
Last Name Role Affiliation
Carlos Prada, MD Principal Investigator Children's Hospital Medical Center, Cincinnati
Overall Contact

Last Name: Lindsey Aschbacher-Smith, MS

Phone: 513-803-0077

Email: [email protected]

Location
Facility: Status: Contact: Contact Backup: Investigator: Cincinnati Children's Hospital Medical Center Lindsey Aschbacher-Smith, MS 513-803-0077 [email protected] Carlos E Prada, MD Principal Investigator
Location Countries

United States

Verification Date

May 2020

Responsible Party

Type: Sponsor

Has Expanded Access No
Condition Browse
Arm Group

Label: Neurofibromatosis 1 (NF1)

Description: Individuals with a confirmed or suspected diagnosis of Neurofibromatosis Type 1 (NF1). Diagnosis may be made clinically and/or confirmed through genetic testing. Clinical (non-genetic) diagnosis requires that individuals meet the National Institute of Health's (NIH) clinical diagnostic criteria for NF1.

Label: Noonan Syndrome

Description: Individuals with a confirmed or suspected diagnosis of Noonan Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.

Label: Noonan Syndrome with Multiple Lentigines

Description: Individuals with a confirmed or suspected diagnosis of Noonan Syndrome with Multiple Lentigines. Diagnosis may be made clinically and/or confirmed through genetic testing.

Label: Noonan Neurofibromatosis Syndrome

Description: Individuals with a confirmed or suspected diagnosis of Noonan Neurofibromatosis Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.

Label: Cardiofaciocutaneous Syndrome

Description: Individuals with a confirmed or suspected diagnosis of Cardiofaciocutaneous Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.

Label: Costello Syndrome

Description: Individuals with a confirmed or suspected diagnosis of Costello Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.

Label: Legius Syndrome

Description: Individuals with a confirmed or suspected diagnosis of Legius Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.

Label: Smith-Kingsmore Syndrome

Description: Individuals with a confirmed or suspected diagnosis of Smith-Kingsmore Syndrome. Diagnosis may be made clinically and/or confirmed through genetic testing.

Label: GATOR-1 Mutation

Description: Individuals with a suspected or known mutation of GATOR-1.

Label: SYNGAP1-Related Intellectual Disability

Description: Individuals with a suspected or known mutation of SYNGAP1.

Label: DLG4 Mutation

Description: Individuals with a suspected or known mutation of DLG4.

Label: MAPK1 Gene Mutation

Description: Individuals with a suspected or known mutation of MAPK1.

Label: MTOR Gene Mutation

Description: Individuals with a suspected or known mutation of a gene associated with the MTOR cellular pathway. Diagnosis may be made clinically and/or confirmed through genetic testing. Unaffected relatives of individuals with a suspected or known mutation of a gene associated with the MTOR cellular pathway.

Label: RAS Mutation

Description: Individuals with a suspected or known mutation of a gene associated with the RAS/MAPK cellular pathway. Diagnosis may be made clinically and/or confirmed through genetic testing. Unaffected relatives of individuals with a suspected or known mutation of a gene associated with the RAS/MAPK cellular pathway.

Patient Data No
Study Design Info

Observational Model: Cohort

Time Perspective: Prospective

Source: ClinicalTrials.gov

Clinical Research News